Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metasta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Clin Oncol
Päätekijät: Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, Uemura, Hiroji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Japan 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809574/
https://ncbi.nlm.nih.gov/pubmed/28770408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-017-1176-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia